Molecular Medicine

, Volume 18, Issue 2, pp 250–259 | Cite as

Redox Modification of Cysteine Residues Regulates the Cytokine Activity of High Mobility Group Box-1 (HMGB1)

  • Huan Yang
  • Peter Lundbäck
  • Lars Ottosson
  • Helena Erlandsson-Harris
  • Emilie Venereau
  • Marco E. Bianchi
  • Yousef Al-Abed
  • Ulf Andersson
  • Kevin J. Tracey
  • Daniel J. Antoine
Research Article


High mobility group box 1 (HMGB1) is a nuclear protein with extracellular inflammatory cytokine activity. It is released passively during cell injury and necrosis, and secreted actively by immune cells. HMGB1 contains three conserved redox-sensitive cysteine residues: C23 and C45 can form an intramolecular disulfide bond, whereas C106 is unpaired and is essential for the interaction with Toll-Like Receptor (TLR) 4. However, a comprehensive characterization of the dynamic redox states of each cysteine residue and of their impacts on innate immune responses is lacking. Using tandem mass spectrometric analysis, we now have established that the C106 thiol and the C23-C45 disulfide bond are required for HMGB1 to induce nuclear NF-κB translocation and tumor necrosis factor (TNF) production in macrophages. Both irreversible oxidation to sulphonates and complete reduction to thiols of these cysteines inhibited TNF production markedly. In a proof of concept murine model of hepatic necrosis induced by acetaminophen, during inflammation, the predominant form of serum HMGB1 is the active one, containing a C106 thiol group and a disulfide bond between C23 and C45, whereas the inactive form of HMGB1, containing terminally oxidized cysteines, accumulates during inflammation resolution and hepatic regeneration. These results reveal critical posttranslational redox mechanisms that control the proinflammatory activity of HMGB1 and its inactivation during pathogenesis.



This work was supported by grants from the Feinstein Institute for Medical Research, General Clinical Research Center (M01RR018535), from the National Institute for General Medical Science (NIGMS, to KJ Tracey), from NIGMS (GM098446, to H Yang) the Associazione Italiana Ricerca sul Cancro (to ME Bianchi) and from the Swedish Medical Research Council (to U Andersson and H Erlandsson-Harris). DJ Antoine is supported by the Medical Research Council (UK), grant number G0700654, and E Venereau by a fellowship from Associazione Italiana Ricerca sul Cancro.


  1. 1.
    Andersson U, Rauvala H. (2011) Introduction: HMGB1 in inflammation and innate immunity. J. Intern. Med. 270:296–300.CrossRefPubMedGoogle Scholar
  2. 2.
    Yang H, et al. (2010) A critical cysteine is required for HMGB1 binding to Toll-like receptor 4 and activation of macrophage cytokine release. Proc. Natl. Acad. Sci. U. S. A. 107:11942–7.CrossRefPubMedGoogle Scholar
  3. 3.
    Wang H, et al. (1999) HMG-1 as a late mediator of endotoxin lethality in mice. Science. 285:248–51.CrossRefPubMedGoogle Scholar
  4. 4.
    Antoine DJ, et al. (2010) Diet restriction inhibits apoptosis and HMGB1 oxidation and promotes inflammatory cell recruitment during acetaminophen hepatotoxicity. Mol. Med. 16:479–90.CrossRefPubMedGoogle Scholar
  5. 5.
    Schierbeck H, et al. (2011) Monoclonal anti-HMGB1 antibody protection in two experimental arthritis models. Mol. Med. 17:1039–44.CrossRefPubMedGoogle Scholar
  6. 6.
    Bianchi ME, Beltrame M, Paonessa G. (1989) Specific recognition of cruciform DNA by nuclear protein HMG1. Science. 243:1056–9.CrossRefPubMedGoogle Scholar
  7. 7.
    Li J, et al. (2003) Structural basis for the proinflammatory cytokine activity of high mobility group box 1. Mol. Med. 9:37–45.CrossRefPubMedGoogle Scholar
  8. 8.
    Kazama H, et al. (2008) Induction of immunological tolerance by apoptotic cells requires caspase-dependent oxidation of high-mobility group box-1 protein. Immunity. 29:21–32; comment, 29:1-2. See comment.CrossRefPubMedGoogle Scholar
  9. 9.
    Sahu D, et al. (2008) Redox properties of the Adomain of the HMGB1 protein. FEBS Lett. 582:3973–8.CrossRefPubMedGoogle Scholar
  10. 10.
    Stott K, et al. (2010) Tail-mediated collapse of HMGB1 is dynamic and occurs via differential binding of the acidic tail to the A and B domains. J. Mol. Biol. 403:706–22.CrossRefPubMedGoogle Scholar
  11. 11.
    Li J, et al. (2004) Recombinant HMGB1 with cytokine-stimulating activity. J. Immunol. Methods. 289:211–23.CrossRefPubMedGoogle Scholar
  12. 12.
    Antoine DJ, et al. (2009) High Mobility Group Box-1 protein and Keratin-18, circulating serum proteins informative of acetaminophen-induced necrosis and apoptosis in vivo. Toxicol. Sci. 112:521–31.CrossRefPubMedGoogle Scholar
  13. 13.
    Scaffidi P, Misteli T, Bianchi ME. (2002) Release of chromatin protein HMGB1 by necrotic cells triggers inflammation. Nature. 418:191–5.CrossRefPubMedGoogle Scholar
  14. 14.
    Chen GY, et al. (2009) CD24 and Siglec-10 selectively repress tissue damage-induced immune responses. Science. 323:1722–5.CrossRefPubMedGoogle Scholar
  15. 15.
    Spickett CM, Pitt AR. (2010) Protein oxidation: role in signalling and detection by mass spectrometry. Amino Acids. 42:5–21.CrossRefPubMedGoogle Scholar
  16. 16.
    Rubartelli A, Lotze MT. (2007) Inside, outside, upside down: damage-associated molecular-pattern molecules (DAMPs) and redox. Trends Immunol. 28:429–36.CrossRefPubMedGoogle Scholar
  17. 17.
    Vezzoli M, et al. (2010) Redox remodeling: a candidate regulator of HMGB1 function in injured skeletal muscle. Ann. N. Y. Acad. Sci. 1209:83–90.CrossRefPubMedGoogle Scholar
  18. 18.
    Park S, Lippard SJ. (2011) Redox state-dependent interaction of HMGB1 and cisplatin-modified DNA. Biochemistry. 50:2567–74.CrossRefPubMedGoogle Scholar
  19. 19.
    Hogg PJ. (2003) Disulfide bonds as switches for protein function. Trends Biochem. Sci. 28:210–4.CrossRefPubMedGoogle Scholar
  20. 20.
    Hoppe G, et al. (2006) Molecular basis for the redox control of nuclear transport of the structural chromatin protein Hmgb1. Exp. Cell Res. 312:3526–38.CrossRefPubMedGoogle Scholar
  21. 21.
    Tang D, et al. (2010) Endogenous HMGB1 regulates autophagy. J. Cell Biol. 190:881–92.CrossRefPubMedGoogle Scholar
  22. 22.
    Bonaldi T, et al. (2003) Monocytic cells hyperacetylate chromatin protein HMGB1 to redirect it towards secretion. EMBO J. 22:5551–60.CrossRefPubMedGoogle Scholar
  23. 23.
    Andersson U, et al. (2000) High mobility group 1 protein (HMG-1) stimulates proinflammatory cytokine synthesis in human monocytes. J. Exp. Med. 192:565–70.CrossRefPubMedGoogle Scholar
  24. 24.
    Hreggvidsdottir HS, et al. (2009) The alarmin HMGB1 acts in synergy with endogenous and exogenous danger signals to promote inflammation. J. Leukoc. Biol. 86:655–62.CrossRefPubMedGoogle Scholar

Copyright information

© The Author(s) 2012

Open Access This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, and provide a link to the Creative Commons license. You do not have permission under this license to share adapted material derived from this article or parts of it.

The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder.

To view a copy of this license, visit (

Authors and Affiliations

  • Huan Yang
    • 1
  • Peter Lundbäck
    • 2
  • Lars Ottosson
    • 2
  • Helena Erlandsson-Harris
    • 2
  • Emilie Venereau
    • 3
  • Marco E. Bianchi
    • 3
  • Yousef Al-Abed
    • 4
  • Ulf Andersson
    • 2
  • Kevin J. Tracey
    • 1
  • Daniel J. Antoine
    • 5
  1. 1.Laboratory of Biomedical ScienceThe Feinstein Institute for Medical ResearchManhassetUSA
  2. 2.Departments of Women’s and Children’s Health, Medicine and Rheumatology Research LaboratoryKarolinska Institutet and Karolinska University HospitalStockholmSweden
  3. 3.San Raffaele University and Scientific InstituteMilanItaly
  4. 4.Department of Medicinal ChemistryThe Feinstein Institute for Medical ResearchManhassetUSA
  5. 5.MRC Centre for Drug Safety Science, Department of Molecular and Clinical PharmacologyUniversity of LiverpoolLiverpoolUK

Personalised recommendations